Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-01-27FDA Approved: ONDANSETRON HYDROCHLORIDE — Original Application (Chartwell RX, LLC.)
FDA approved an original ANDA for ondansetron hydrochloride (generic) by Chartwell RX, LLC, expanding available generic options for the anti…
-
FDA approval · 2011-01-20FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for ondansetron hydrochloride from NorthStar Rx LLC, confirming continued approval of this generic a…
-
FDA approval · 2011-01-04FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Aurobindo Pharma Limited, adding a new generic product under an A…
-
FDA approval · 2010-12-08FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc. under the ANDA process, indicating an approved…
-
CLINICAL_TRIALS trial_result · 2010-12-02Clinical Trial Update: A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting [Phase 4]
Phase IV trial of Cesamet (nabilone) plus standard antiemetic therapy for chemotherapy-induced nausea and vomiting has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-11-30FDA Approved: ONDANSETRON — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Dr. Reddy's Laboratories Limited, allowing continued approval…
-
FDA approval · 2010-11-30FDA Approved: ONDANSETRON — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for ondansetron submitted by Hikma Pharmaceuticals USA, indicating a regulatory update to the pr…
-
FDA approval · 2010-11-12FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2010-10-29FDA Approved: DRONABINOL — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for dronabinol from Rhodes Pharmaceuticals L.P., enabling a generic dronabinol product.
-
CLINICAL_TRIALS trial_result · 2010-09-17Clinical Trial Update: Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting [Phase 2]
Phase 2 clinical trial results for Palonosetron in preventing chemotherapy-induced nausea and vomiting have been completed, reporting safety…
-
FDA approval · 2010-09-15FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Bionpharma Inc.)
The FDA has approved a supplemental application for granisetron hydrochloride submitted by Bionpharma Inc., maintaining regulatory approval …
-
CLINICAL_TRIALS trial_result · 2010-08-26Clinical Trial Update: A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) [Phase 1]
Phase 1 bioequivalence study in healthy adults comparing three formulations of ondansetron for prevention of chemotherapy-induced nausea and…
-
CLINICAL_TRIALS trial_result · 2010-06-30Clinical Trial Update: A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165) [Phase 1]
This Phase 1 study assessed bioequivalence between aprepitant and fosaprepitant and evaluated the effect of food on aprepitant bioavailabili…
-
CLINICAL_TRIALS trial_result · 2010-06-22Clinical Trial Update: Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) [Phase 1]
A Phase 1 bioequivalence study comparing two ondansetron formulations in healthy adults, with results posted.
-
FDA approval · 2010-06-03FDA Approved: METOCLOPRAMIDE — Supplemental Application (Teva Parenteral Medicines, Inc.)
FDA approved a supplemental application for metoclopramide from Teva Parenteral Medicines, Inc., updating the product's approval status as p…
-
CLINICAL_TRIALS trial_result · 2010-05-10Clinical Trial Update: Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy [Phase 2]
A Phase 2 clinical trial completed evaluating prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly eme…
-
FDA approval · 2010-04-12FDA Approved: ONDANSETRON — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for generic ondansetron by Rising Pharma Holdings, Inc. for prevention of nausea and vomiting in posto…
-
FDA approval · 2010-04-09FDA Approved: GRANISETRON HYDROCHLORIDE — Original Application (Mylan Institutional LLC)
FDA approved Mylan Institutional LLC's Original Application for granisetron hydrochloride, a generic version of granisetron. The approval co…
-
FDA approval · 2010-04-09FDA Approved: GRANISETRON HYDROCHLORIDE — Original Application (Mylan Institutional LLC)
FDA approved granisetron hydrochloride under an original generic application (ANDA) for preventing nausea and vomiting caused by chemotherap…
-
FDA approval · 2010-03-31FDA Approved: METOCLOPRAMIDE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals’ supplemental application for metoclopramide, updating the regulatory status of this generic drug.
-
FDA approval · 2010-03-23FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2010-02-12Clinical Trial Update: Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) [Phase 3]
A Phase 3 study evaluating a single-dose fosaprepitant (MK0517) regimen for preventing chemotherapy-induced nausea and vomiting has been com…
-
FDA approval · 2009-12-23FDA Approved: GRANISETRON HYDROCHLORIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approves an original application for granisetron hydrochloride (generic) by Hikma Pharmaceuticals USA Inc. as a generic antiemetic to pr…
-
FDA approval · 2009-12-01FDA Approved: METOCLOPRAMIDE — Supplemental Application (Ipca Laboratories Limited)
FDA approved Ipca Laboratories Limited's supplemental application for Metoclopramide, granting approval of a generic version of the drug. Th…
-
CLINICAL_TRIALS trial_result · 2009-11-25Clinical Trial Update: Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy [Phase 2]
Phase 2 study evaluating palonosetron alone for preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive no…